US FDA’s Rx Drug Promo Study Answers $798,000 Question
Viewers spend more time on print ads that have more lengthy important safety information or a brief summary but impact on understanding is unclear, OPDP study finds. Another study finds exaggerated images of drug benefits in TV ads unsurprisingly can mislead consumers.
You may also be interested in...
Office of Prescription Drug Promotion’s latest study is assessing consumer and physician responses to prescription drug promotions with claims about patient adherence and preference. It is one of 73 research projects OPDP has undertaken.
In first Rx advertising research project of 2023, FDA will survey consumers on how they interpret quantitative claims in DTC ads. Lilly questions design of another study examining relative importance of product information, citing FDA comments at tanezumab advisory committee.
US FDA study finds that sales aids for oncology drugs that disclose a study’s data limitations and clinical uncertainty can lead to more appropriate assessments of the data by physicians but does not affect their overall perceptions of a drug’s benefits.